BIOCON SDN BHD, MALAYSIA – MAKING A DIFFERENCE IN MALAYSIA AND BEYOND
Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals. More recently, Biocon’s biosimilar insulin Glargine made at Malaysia received a historic U.S. FDA approval as the ‘first interchangeable biosimilar’.
Through Biocon Sdn Bhd, Biocon Biologics has set up Asia’s largest integrated insulin manufacturing and R&D facility in Malaysia at an investment of over USD 350 million. This is the largest foreign investment in biotechnology in Malaysia, reflecting Biocon Biologics’ commitment to put affordable life-changing insulins within the reach of patients across the world. Commercial operations at the facility commenced in 2016 when Biocon Biologics’ recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia.
As the only insulin manufacturer in Malaysia, Biocon Sdn Bhd has been able to ensure insulin self-sufficiency for Malaysia and improve insulin access while providing savings to its partner, Ministry of Health (MoH), Malaysia. Since Biocon’s entry into Malaysia in 2011, prices of human insulin have dropped by over 40% and insulinization has also improved by 30%.
Biocon Biologics is addressing the global need for high quality insulins at affordable prices through our Center of Excellence (CoE) for insulins in Malaysia.
Through the insulins manufactured at this facility, Biocon Sdn Bhd is also making a difference to the lives of millions of people with diabetes worldwide by providing them affordable access to life-saving insulin therapy.
The scientifically validated, high quality human insulin and analog products manufactured at the facility in Johor, Malaysia, are benefiting patients in many developed markets like U.S., EU, Australia, as well as many emerging market countries in the Middle East and Latin America.
The 562,000 sq. ft. facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by the prestigious Malaysia Book of Records, the official, record-keeping body of Malaysia.
Encouraged by the demand for its current insulin portfolio globally and the pipeline ahead of it, Biocon Biologics has initiated investments to expand our insulins manufacturing facility in Malaysia.